On Tuesday, the NASDAQ Composite ended the trading session at 5,283.40, down 0.50%; the Dow Jones Industrial Average edged 0.30% lower, to finish at 18,169.27; and the S&P 500 closed at 2,143.16, down 0.38%. This morning, Stock-Callers.com looks at the performance of the following Generic Drugs stocks: Patheon Holdings Cooperatief U.A., Momenta Pharmaceuticals Inc., Diplomat Pharmacy Inc., and Karyopharm Therapeutics Inc.
Patheon
On Tuesday, shares in Amsterdam, the Netherlands-based Patheon Holdings Cooperatief U.A. ended the session 4.25% lower at $27.50 with a total volume of 305,078 shares traded. Shares of Patheon have gained 10.00% in the previous three months. Shares of the Company, which provides outsourced pharmaceutical development and manufacturing services, are trading at a PE ratio of 29.60. The stock is trading 3.38% below its 50-day moving average and 0.79% below its 200-day moving average. Moreover, shares of the Company have a Relative Strength Index (RSI) of 38.80.
Momenta Pharma
Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc.’s stock finished Tuesday’s session 0.59% lower at $11.80 with a total volume of 291,921 shares traded. Over the last one month and the previous three months, Momenta Pharmaceuticals’ shares have advanced 1.37% and 0.77%, respectively. Shares of the Company, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases, are trading above its 200-day moving average by 7.71%. Momenta Pharmaceuticals’ stock has an RSI of 47.36.
On October 11th, 2016, research firm Barclays upgraded the Company’s stock rating from ‘Equal Weight’ to ‘Overweight’. The research firm also revised upwards its previous target price from $13 to $19.
Diplomat Pharmacy
Flint, Michigan headquartered Diplomat Pharmacy Inc.’s stock edged 0.24% lower, to close the day at $28.88. The stock recorded a trading volume of 345,997 shares. Shares of Diplomat Pharmacy, which stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers, have gained 15.38% in the past one year. The Company’s shares are trading 4.77% and 7.40% below its 50-day and 200-day moving averages, respectively. Additionally, the stock traded at a PE ratio of 44.36 and has an RSI of 50.12.
Karyopharm Therapeutics
On Tuesday, shares in Newton, Massachusetts headquartered Karyopharm Therapeutics Inc. recorded a trading volume of 165,727 shares. The stock ended the day 0.35% lower at $8.45. Karyopharm Therapeutics’ stock has gained 10.17% in the last three months. The Company is trading above its 200-day moving average by 5.36%. Furthermore, shares of Karyopharm Therapeutics, which focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases, have an RSI of 45.12.
To view the full press release, click here.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
